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Objective In order to evaluate the interlaboratory variation of HIV-1 RNA measurements in plasma, the
Belgian AIDS reference laboratories organized a blinded multicenter quality control study.
Methods A test panel of coded spiked HIV-1 plasma samples reflecting the dynamic range of the assay was
composed and distributed. The HIV-1 RNA concentration of these samples was determined by the eight
Belgian AIDS reference laboratories by means of the Amplicor HIV-1 Monitor version 1.5 assay.
Results Analysis of the results demonstrated that there was little interlaboratory variation for the high
concentration range (4.0–5.7 log10 copies/mL), never exceeding 0.2 log10 copies/mL. However the standard
deviation for the low concentration range (2.6–3.9 log10 copies/mL) reached up to 0.22 log10 copies/mL.
Conclusions Since interlaboratory variability never reached 0.5 log10 copies/mL and each of the laboratories
was able to detect four-fold differences in plasma HIV-1 RNA levels, the Amplicor assay can be used in
multicenter studies without a centralized analysis of samples. Furthermore, this well-characterized proficiency
panel of spiked plasma samples could be used as a standard in the study of interassay comparisons.
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INTRODUCTION
Quantification of human immunodeficiency virus type 1 (HIV-
1) RNA has been shown to be essential in predicting the
rate of disease progression and in monitoring antiretrovirus
treatment.
Initially, most of the HIV-1 RNA quantification assays were
performed with in-house polymerase chain reaction (PCR)-
based methods [1–5]. In general, these methods were laborious
and lacked proper quality assurance and quality control. These
in-house methods were soon replaced by first generation com-
mercial assays, which were evaluated in different studies [6–9].
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Later, the introduction of second generation commercial assays
[10,11] resolved some but not all of the problems of the first
generation products with regards to sensitivity, specificity,
reproducibility, performance on different HIV-1 subtypes and
lower limit of detection [12–21]. Meanwhile, commercial assays
for determining HIV-1 RNA load became widely used in the
follow-up of HIV-infected patients as well as in antiretroviral
therapy-related clinical trials. Most of these trials concerned
multicenter studies, national or international, with laboratory
tests being performed at the local sites. To allow comparisons
and to draw valid conclusions, there is an urgent need for
studies evaluating the interlaboratory variation of HIV-1 RNA
measurements in plasma.
To address this, the Belgian AIDS reference laboratories
(ARL) organized a blinded multicenter quality control study
for the quantification of HIV-1 RNA in plasma by means of a
proficiency panel which might be used in the future for the
evaluation of new commercial assays or assays developed in-
house.
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MATERIALS AND METHODS
Quantitative HIV-1 RNA assay and participating laboratories
All eight Belgian AIDS reference laboratories participating in
this quality control study agreed to determine the HIV-1 RNA
concentration with the Amplicor HIV-1 Monitor version 1.5
assay (Roche Diagnostics, Branchburg, NJ, USA). Since the
ARL of the Academisch Ziekenhuis – Vrije Universiteit Brussel
(AZ-VUB) is divided into two physically separated units (AZ-
VUB and UMC St-Pieter), the preparation and distribution of
the samples as well as the statistical analysis was performed in
one unit (later called the organizing laboratory) allowing the
second unit to participate in the blinded quality control study.
All participating laboratories had prior experience with the assay
and it is used on a routine basis in most. The linear range of
the assay is 400–750 000 HIV-1 RNA copies/mL (2.60–5.87
log10 copies/mL) as determined by the manufacturer. The lot
number of the kits used in the study was recorded by each
ARL.
Preparation of a master stock
An HIV-1 master stock was prepared by coculturing peripheral
blood mononuclear cells (PBMC) from an HIV-1 infected
patient with seronegative donor PBMC as previously described
[22]. After 2 weeks, the culture fluid was separated from the
cells by centrifugation at 10 000 g for 1 minute, aliquoted and
stored at –70 °C. The selected HIV-1 strain belonged to subtype
B for both env and gag as determined by the heteroduplex
mobility assay [23,24].
Preparation of a reference panel
A coded panel was prepared by means of 23 sequential two-
fold dilutions of an aliquot of the diluted master stock initially
diluted 1/500 in HIV-seronegative plasma. Each dilution step
resulted in 25 mL of spiked HIV-1 positive plasma, which was
subsequently aliquoted in 0.6 mL fractions, and stored at
–70 °C. Based upon a preliminary HIV-1 RNA quantification
in the organizing laboratory, 17 dilutions covering the detection
range (2.6–5.8 log10 copies/mL) of the Amplicor HIV-1 Moni-
tor version 1.5 assay were selected to be included in the test
panel for the quality control study.
Multicenter quality control study
Aliquots of 10 out of 17 selected dilutions from the test panel
were randomly selected for each participating laboratory and
shipped to the eight testing sites. The study thus involved the
quantification of plasma HIV-1 RNA in a total of 80 samples
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from the 17 spiked HIV-1 plasma dilutions by the eight ARL
(Table 1).
HIV-1 RNA quantification
The HIV-1 RNA quantification of the 10 blinded samples was
performed using the Amplicor HIV-1 Monitor version 1.5
assay according to the manufacturer’s protocol. An inde-
pendently run control with a mean HIV-1 RNA concentration
of about 10 000 copies/mL [25] was enclosed in each run
and the results were recorded. The data were collected in the
organizing laboratory for further statistical analysis.
Statistical analysis
Results were expressed as log10 HIV-1 RNA copies per ml of
plasma. Values lower than the detection limit (2.6 log10 HIV-1
RNA copies/mL) were omitted for the statistical analysis. The
mean, the standard deviation (SD), the correlation coefficient
and the slope were calculated by use of the Microsoft Office
Excel software (Redmond, USA). The coefficient of variation
was calculated by the same software on the values expressed as
RNA copies/mL and not as log10 RNA copies/mL. Similarly,
the statistical comparison using Kruskal–Wallis t-test was cal-
culated on the values expressed as RNA copies/mL by the
software Statistica (StadSoft, Tulsa, OK, USA).
Since the data from the organizing ARL were not obtained
in a blinded way, they were not included in the statistical
analysis.
RESULTS
The SD for all samples yielding quantitative results in the linear
range of the assay (2.6–5.9 log10copies/mL) varied between
0.07 and 0.22 with a mean of 0.15 log10 units (Table 1). The
coefficient of variation in the same linear range varied between
16 and 51% (data not shown). In the lower part of the linear
range (2.6–3.9 log10 copies/mL), the SD was higher (up to 0.22
log10 units) than in the higher concentration range (4.0–5.7
log10 units) where it never exceeded 0.20 log10 units. For the
independent run control, a mean of 4.01 log10 copies/mL was
obtained with a SD of 0.13 log10 units.
Four out of eight laboratories determined the HIV-1 RNA
quantity with the same lot. Three other lots were used by the
four remaining laboratories. No statistically significant
(P = 0.4829) difference could be observed between the SD from
the results obtained by the four laboratories using the same lot
as compared with the overall results (data not shown). No lot
was performing significantly better across the range of dilutions
tested.
Furthermore, all the laboratories participating in this blinded
study were able to differentiate four-fold differences in HIV-1
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Table 1 Comparative study of the data (in log10 copies/mL) obtained by the eight AIDS reference laboratories (ARL)
Dilution
Sample code factor* ARL1 ARL2 ARL3 ARL4 ARL5 ARL6 ARL7 ARL8 Mean SD**
A16 131072  2.60  2.60  2.60  2.60  2.60  2.60
A14 65536  2.60  2.60  2.60  2.60
A8 32768  2.60  2.60  2.60  2.60  2.60  2.60
A3 16384  2.60  2.60  2.60  2.60  2.60  2.60
A1 8192  2.60  2.60  2.60  2.60  2.60  2.60
A13 4096 2.65 2.84  2.60  2.60  2.60
A15 2048  2.60 2.98  2.60  2.60  2.60
A23 1024 3.19 2.90 2.91 3.00 0.17
A6 512 2.98 3.21 3.24 2.90 3.40 3.15 0.20
A2 256 3.82 3.38 3.34 3.76 3.47 3.55 0.22
A24 128 3.56 3.83 3.67 3.73 3.48 3.87 3.70 0.16
A18 64 4.15 4.02 4.02 3.96 4.04 4.04 0.07
A11 32 4.35 4.61 4.26 4.10 4.33 4.32 0.19
A9 16 4.86 4.57 4.69 4.46 4.66 0.16
A5 8 4.78 4.95 4.84 4.82 4.85 0.07
A7 4 5.37 5.29 5.06 5.39 5.49 5.32 0.16
A19 2 5.53 5.43 5.39 5.63 5.49 5.23 5.41 5.44 0.13
* dilution factor from the master stock (  1000).
** SD, standard deviation.
RNA levels and to order the samples correctly in the range
2.6–5.0 log10 copies/mL according to their HIV-1 RNA copy
number (Table 1).
As shown in Figure 1, a significant linear relationship was
observed between the mean HIV-1 RNA levels and the
dilution factor with a coefficient of correlation of – 0.998 and
a slope of – 0.930.
Figure 1 Correlation between the mean HIV-1 RNA levels as
measured with the HIV-1 Monitor version 1.5 assay and
the dilution factor of the samples. The dashed line represents
the lower limit of detection. Correlation: –0.998, slope:
– 0.930.
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DISCUSSION
Direct viral load measurements can be obtained through a
number of commercially available assays. The performance of
these assays has already been investigated by comparative studies
[12–17], showing that most of them suffer poor intra-run and
inter-run reproducibility ranging up to 0.5 log10 units [17].
The quality assurance program as established by the Virology
Committee of the AIDS Clinical Trial Group in the division
of AIDS, National Institute of Allergy and Infectious Diseases,
U.S.A., required an intra-assay SD of less than 0.15 log10 RNA
copies per ml in order to achieve the degree of precision that
will provide 90% power to detect a five-fold difference in RNA
concentration between two samples [26]. However in this pro-
gramme no information on the inter-run reproducibility was
reported.
Since testing in batches would mean unacceptable delays for
managing individual patients, the Belgian ARL decided that it
was essential to collect more data about the inter-run variability
of HIV-1 RNA quantification. In order to do so, they have
included since January 1998 in every run of the Amplicor HIV-
1 Monitor assay an independent run control whose mean value
is about 10 000 HIV-1 RNA copies/mL. The SD of this inde-
pendent run control within the Belgian ARL varies between
0.14 and 0.21 log10 units with a mean for these eight laboratories
of 0.19 log10 units.
The primary goal of this quality control study was to deter-
mine the interlaboratory variation by means of a coded pro-
ficiency panel, covering the whole linearity range of the assay
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and not solely through one HIV-1 RNA concentration as
measured by means of the independent run control. The inter-
laboratory variation was higher in the low concentration range
(2.6–3.9 log10 copies/mL) as compared with the high con-
centration range (4.0–5.7 log10 copies/mL). In the latter the SD
for six out of six samples (Table 1) was equal or inferior to the
mean of the SD (0.19 log10 units) of the independent run
control, suggesting that the interlaboratory variation was not
significant. Although for the low concentration range, the SD
for two out of four samples was higher than the mean SD of
the independent run control, however, it did not exceed 0.22
log10 units. Moreover, there was no evidence of significant
interlot variation with the four lot numbers used by the eight
participating laboratories.
Thus our results indicate that the interlaboratory variability
experienced for the HIV-1 RNA determinations are within
0.5 log10 units which is clinically acceptable at present. These
data also suggest that HIV-1 RNA determinations are appro-
priate for use in multicenter studies and that there is no apparent
need for a centralized analysis of samples nor for batch testing,
since lot variation and interlaboratory variation does not seem
to be a critical issue.
A second conclusion of this quality control programme is
that the estimates of RNA copy number for samples which
differed by four-fold in actual copy number could accurately
be differentiated by all the Belgian ARL. All the laboratories
participating in this blinded study were able to order the samples
correctly in the range 2.6–5.0 log10 copies/mL according to
their HIV-1 RNA copy number.
The secondary goal of our study was to build a reference
panel which can be used by the Belgian ARL to evaluate the
linear range of detection of new HIV-1 RNA quantification
kits or new versions of already existing kits. This was achieved
through the determination of the mean HIV-1 RNA con-
centrations obtained in our multicenter quality control study
(samples A23 through A19 in Table 1).
At present the goal of the highly active antiretroviral treat-
ment (HAART) is to lower the viral load to undetectable levels,
i.e. 1.7 log10 copies/mL. In future, our reference panel will be
of utmost importance to test the variability in the range 1.7–
2.6 log10 copies/mL which is presently unknown.
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